| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Interim CEO & General Counsel
1 company
Frederick G Vogt is Interim CEO & General Counsel at IOVA. Frederick G Vogt's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.3M at current prices.
Historically, Frederick G Vogt's trades have earned a middling insider score of 59/100 across 3 rated trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +15.2%.
Net of sales, the IOVA filings show accumulation of 27,000 shares.
Frederick G Vogt has 36 Form 4 filings on record from December 2017 to September 2026, all as Interim CEO & General Counsel at Iovance Biotherapeutics (IOVA), 2017–2026.
The 66 reported transactions were 25 option exercises, 25 tax withholdings, 13 option or other derivative awards and 3 open-market purchases.
Counted by filing, the open-market trades come to 3 purchases worth about $55K and no sales.
The largest open-market purchase was 25,000 shares of IOVA at an average $1.69 on May 14, 2025, about $42K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2025 | IOVA Iovance Biotherapeutics, Inc. | Interim CEO & General Counsel | Buy | 25,000 | $1.69 | $42,250.00 | +7.2% | +30.8% | - | |
| Nov 28, 2022 | IOVA Iovance Biotherapeutics, Inc. | Interim CEO & General Counsel | Buy | 1,000 | $5.98 | $5,980.00 | +100.0% | +20.5% | -6.4% | |
| Jun 1, 2022 | IOVA Iovance Biotherapeutics, Inc. | Interim CEO & General Counsel | Buy | 1,000 | $6.44 | $6,440.00 | New | +63.8% | +36.8% |